, Volume 105, Issue 4, pp 558–562 | Cite as

Exploring the pharmacology of the pro-convulsant effects of α2-adrenoceptor antagonists in mice

  • Helen C. Jackson
  • S. L. Dickinson
  • D. J. Nutt
Original Investigations


The effects of selective and specific α2-adrenoceptor antagonists on electroshock seizure threshold in mice were investigated. Idazoxan, at low doses, efaroxan, RX811059 and RX821002 significantly lowered seizure threshold. The α1-agonist St 587 and the β-agonist isoprenaline were also pro-convulsant. On the other hand the α2-agonists clonidine and UK 14,304 produced small increases in seizure threshold. Anticonvulsant effects were also produced by low doses of the noradrenaline uptake inhibitor desipramine. This compound increases levels of noradrenaline in the synaptic cleft which could subsequently act at post-synaptic α2-adrenoceptors. The pro-convulsant action of α2-adrenoceptor antagonists could be explained in terms of two mechanisms: a) blockade of endogenous noradrenaline which may normally exert a tonic anti-convulsant influence on seizure threshold, through post-synaptic α2-receptors and/or b) increased activation of α1- and β-adrenoceptors by elevated synaptic noradrenaline levels following blockade of pre-synaptic α2-adrenoceptors. Of the α2-antagonists tested, idazoxan was unusual in that high doses were not pro-convulsant; this difference may be explained by α1-adrenoceptor mediated actions or be related to its recently described affinity at a non-adrenoceptor site — a function for which is currently unknown.

Key words

Electroshock seizure threshold Selective α2- adrenoceptor antagonists Noradrenaline α1-adrenoceptors α2-adrenoceptors β-adrenoceptors Mice 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Cambridge D (1981) UK-14,304, a potent and selective α2-agonist for the characterization of α-adrenoceptor subtypes. Eur J Pharmacol 72:413–415CrossRefPubMedGoogle Scholar
  2. Carlsson A, Fuxe K, Hamberger B, Lindqvist M (1966) Biochemical and histochemical studies on the effects of imipramine-like drugs and (+)-amphetamine on central and peripheral catecholamine neurons. Acta Physiol Scand 67:481–489PubMedGoogle Scholar
  3. Chapleo CB, Myers PL, Butler RCM, Davis JA, Doxey JC, Higgins SD, Myers M, Roach AG, Smith CFC, Stillings MR, Welbourn AP (1984) α-Adrenoreceptor reagents. 2. Effects of modification of the 1,4-benzodiazoxan ring system on α-adrenoreceptor activity. J Med Chem 27:570–576CrossRefPubMedGoogle Scholar
  4. Chen G, Ensor CR, Bohner BB (1954) A facilitative action of reserpine on the central nervous system. Proc Soc Exp Biol Med 86:507–510PubMedGoogle Scholar
  5. Crunelli V, Cervo L, Samanin R (1981) Evidence for a preferential role of central noradrenergic neurons in electrically induced convulsions and activity of various anticonvulsants in the rat. In: Morselli PL, Lloyd KG, Loscher W, Meldrum B, Reynolds EH (eds) Neurotransmitters, seizures and epilepsy. Raven Press, New York, pp 195–202Google Scholar
  6. Dalton JCH, Roberts DCS, McIntyre DC (1985) Supersensitivity to the anticonvulsant and proconvulsant activity of clonidine following noradrenaline depletion induced by 6-hydroxydopamine. Psychopharmacology 85:319–322CrossRefPubMedGoogle Scholar
  7. De Jonge A, Van Meel JCA, Timmermans PBMWM, Van Zwieten PA (1981) A lipophilic, selective α1-adrenoceptor agonist: 2-(2-chloro-5-trifluoromethylphenylimino) imidazolidine (St 587). Life Sci 28:2009–2016PubMedGoogle Scholar
  8. Dennis T, L'Heureux R, Carter C, Scatton B (1987) Presynaptic alpha-2 adrenoceptors play a major role in the effects of idazoxan on cortical noradrenaline release (as measured by in vivo dialysis) in the rat. J Pharmacol Exp Ther 241:642–649PubMedGoogle Scholar
  9. Doxey JC, Roach AG, Smith CFC (1983) Studies on RX781094: a selective, potent and specific antagonist of α2-adrenoceptors. Br J Pharmacol 78:489–505PubMedGoogle Scholar
  10. Doxey JC, Lane AC, Roach AG, Smith CFC, Walter DS (1985) Selective α2-adrenoceptor agonists and antagonists. In: Szabadi E, Bradshaw CM, Nahorski SR (eds) Pharmacology of adrenoceptors. MacMillan, New York, pp 13–22Google Scholar
  11. Finney, DJ (1971) Probit analysis. Cambridge University Press, CambridgeGoogle Scholar
  12. Fletcher A, Forster EA (1984) Proconvulsant actions of selective α2-adrenoceptor antagonists. Br J Pharmacol 81:39PGoogle Scholar
  13. Fletcher A, Forster EA (1988) A proconvulsant action of selective α2-adrenoceptor antagonists. Eur J Pharmacol 151:27–34CrossRefPubMedGoogle Scholar
  14. Fuxe K, Ungerstedt U (1968) Histochemical studies on the effect of (+)-amphetamine, drugs of the imipramine group and trypamine on central catecholamine and 5-hydroxytryptamine neurons after intraventricular injection of catecholamine and 5-hydroxytryptamine. Eur J Pharmacol 4:135–144PubMedGoogle Scholar
  15. Gadie B, Tulloch IF (1985) Proconvulsant action of α2-adrenoceptor antagonists in mice: possible involvement of α1-adrenoceptors. Br J Pharmacol 84:192PGoogle Scholar
  16. Goldberg MR, Robertson D (1983) Yohimbine: a pharmacological probe for study of the α2-adrenoceptor. Pharmacol Rev 35:143–180PubMedGoogle Scholar
  17. Jackson HC, Nutt DJ (1991) Differential effects of selective μ, κ- and δ-opioid antagonists on electroshock seizure threshold in mice. Psychopharmacology 103:380–383PubMedGoogle Scholar
  18. L'Heureux R, Dennis T, Curet O, Scatton B (1986) Measurement of endogenous noradrenaline release in the rat cerebral cortex in vivo by transcortical dialysis: effects of drugs affecting noradrenergic transmission. J Neurochem 46:1794–1801PubMedGoogle Scholar
  19. Langin D, Lafontan M, Stillings MR, Paris H (1989) [3H]RX821002: a new tool for the identification of α2A-adrenoceptors. Eur J Pharmacol 167:95–104CrossRefPubMedGoogle Scholar
  20. Lazarova M, Samanin R (1983) Potentiation by yohimbine of pentylenetetrazol-induced seizures in rats: role of α2 adrenergic receptors. Pharmacol Res Commun 15:419–425PubMedGoogle Scholar
  21. Litchfield JT, Wilcoxon F (1949) A simplified method of evaluating dose-effect experiments. J Pharmacol Exp Ther 96:99–113Google Scholar
  22. Lloyd KG, Worms P (1982) Differential effect of yohimbine in several chemical models of convulsions in mice. Br J Pharmacol 77:340PGoogle Scholar
  23. Ludvig N, György L, Vízi ES (1986) Evidence that serotonin receptors are involved in the anticonvulsant effect of yohimbine in mice. Psychopharmacology 88:82–85CrossRefPubMedGoogle Scholar
  24. Mallard N, Tyacke R, Hudson AL, Nutt DJ (1991) Comparative binding studies of [3H]-idazoxan and [3H]-RX821002 in the rat brain. Br J Pharmacol 102:221PGoogle Scholar
  25. McGrath JC, Brown CM, Wilson VG (1989) Alpha-adrenoceptors: a critical review. Med Res Rev 9:407–533PubMedGoogle Scholar
  26. Michel MC, Insel PA (1989) Are there multiple imidazoline binding sites? TIPS 10:342–344PubMedGoogle Scholar
  27. Paciorek PM, Shepperson NB (1983) α1-Adrenoceptor agonist activity of α2-adrenoceptor antagonists in the pithed rat preparation. Br J Pharmacol 79:12–14PubMedGoogle Scholar
  28. Scatton B, Zivkovic B, Dedek J (1980) Antidopaminergic properties of yohimbine. J Pharmacol Exp Ther 215:494–499PubMedGoogle Scholar
  29. Stern MB, Wood JH (1984) Norepinephrine in epilepsy. In: Ziegler MG, Lake CR (eds) Norepinephrine. Williams & Wilkins, Baltimore, pp 142–159Google Scholar
  30. Swinyard EA (1972) Electrically induced convulsions. In: Purpura DP, Penry JK, Tower DB, Woodbury DM, Walter RD (eds) Experimental models of epilepsy-a manual for the laboratory worker. Raven Press, New York, pp 433–458Google Scholar
  31. Walter DS, Flockhart IR, Haynes MJ, Howlett DR, Lane AC, Burton R, Johnson J, Dettmar PW (1984) Effects of idazoxan on catecholamine systems in rat brain. Biochem Pharmacol 33:2553–2557CrossRefPubMedGoogle Scholar
  32. Yeoh PN, Wolf HH (1968) Effects of some adrenergic agents on low frequency electroshock seizures. J Pharm Sci 57:340–342PubMedGoogle Scholar

Copyright information

© Springer-Verlag 1991

Authors and Affiliations

  • Helen C. Jackson
    • 1
  • S. L. Dickinson
    • 1
  • D. J. Nutt
    • 1
  1. 1.Reckitt and Colman Psychopharmacology Unit, Department of PharmacologySchool of Medical SciencesBristolUK

Personalised recommendations